e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension in lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH)
G. Juan, J. Milara, J. L. Ortiz, J. Escriva, M. Ramon, E. Fernandez, J. Cortijo (Valencia, Spain)
Source:
International Congress 2014 – Pulmonary hypertension in lung disease
Session:
Pulmonary hypertension in lung disease
Session type:
Thematic Poster Session
Number:
2344
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Juan, J. Milara, J. L. Ortiz, J. Escriva, M. Ramon, E. Fernandez, J. Cortijo (Valencia, Spain). Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH). Eur Respir J 2014; 44: Suppl. 58, 2344
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Pulmonary hypertension in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT
Source: International Congress 2014 – COPD and PAH related imaging
Year: 2014
Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
The contributing factors to mean pulmonary artery pressure in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Latest insights into chronic care
Year: 2016
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary artery dissection (PAD) in a patient with diffuse interstitial lung disease and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Right ventricular REMODELING in idiopathic pulmonary fibrosis with or without pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept